Universal, no-cost coverage for mifegymiso in BC

Issue: BCMJ, vol. 60 , No. 1 , January February 2018 , Pages 58-60 News

Universal, no-cost coverage for the drug mifegymiso (also known as RU-486) commenced on 15 January 2018. Mifegymiso, an alternative to surgical abortion, is a combination of mifepristone and misoprostol. It can be used to terminate pregnancies at an early stage—up to 9 weeks from the start of the last menstrual period.

Since 11 July 2017, Pharmacare has covered mifegymiso subject to the rules of a person’s Pharmacare plan. Patients under the Fair Pharmacare plan may face an out-of-pocket expense. Currently, the out-of-pocket cost for mifegymiso for individuals without Pharmacare coverage is approximately $300. The Common Drug Review recommended mifegymiso for public coverage in April 2017.

Pharmacists may dispense mifegymiso to patients with a valid prescription. To obtain a prescription, patients must visit a physician or nurse practitioner for an ultrasound to confirm that they do not have an ectopic pregnancy. Health care professionals who will be prescribing or dispensing mifegymiso are encouraged to complete an education program.

Mifegymiso will be available at all participating pharmacies throughout BC. All pharmacies will be able to order the drug as needed, which could take up to 2 business days to receive. Stock of mifegymiso will be available at pharmacies that are rural or remote, or that have previously dispensed high volumes of the medication.

. Universal, no-cost coverage for mifegymiso in BC. BCMJ, Vol. 60, No. 1, January, February, 2018, Page(s) 58-60 - News.



Above is the information needed to cite this article in your paper or presentation. The International Committee of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

About the ICMJE and citation styles

The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.

An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.

BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:

  • Only the first three authors are listed, followed by "et al."
  • There is no period after the journal name.
  • Page numbers are not abbreviated.


For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org

BCMJ Guidelines for Authors

Leave a Reply